Skip to main content
$2.23 -$0.03 (-1.3%)

04:00 PM EDT on 07/26/21

Vascular Biogenics Ltd. (NASDAQ:VBLT)

CAPS Rating: 1 out of 5

Current Price $2.23 Mkt Cap $134.9M
Open $2.24 P/E Ratio 0.00
Prev. Close $2.23 Div. (Yield) $0.00 (0.0%)
Daily Range $2.18 - $2.31 Volume 199,126
52-Wk Range $1.01 - $3.17 Avg. Daily Vol. 610,264


How do you think NASDAQ:VBLT will perform against the market?

Add Stock to CAPS Watchlist

All Players

11 Outperform
9 Underperform

All-Star Players

0 Outperform
7 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:VBLT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

zzlangerhans (97.41)
Submitted June 02, 2016

As my focus shifts to shorting stocks, I've begun entering more red thumbs on low quality bios in which I don't particularly expect short-term declines. The reason is that I don't have time to watch them all and I don't want to miss their eventual… More



Fools bearish on NASDAQ:VBLT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VBLT.


Member Avatar oscillation (75.04) Submitted: 8/24/2018 10:07:49 AM : Outperform Start Price: $1.65 NASDAQ:VBLT Score: -18.77



Member Avatar zzlangerhans (97.41) Submitted: 6/2/2016 6:15:02 PM : Underperform Start Price: $3.64 NASDAQ:VBLT Score: +148.27

As my focus shifts to shorting stocks, I've begun entering more red thumbs on low quality bios in which I don't particularly expect short-term declines. The reason is that I don't have time to watch them all and I don't want to miss their eventual demise. I'm not worried about short-term effects on my CAPS score if they double or triple, because nobody has cared about CAPS scores for years except the top 3 players. If I choose my stocks well, ultimately most of them will become wins eventually. The best part is that if one of my picks becomes a huge loser, it's a good ongoing reminder to keep my eye on it for a possible short.

Vascular Biogenics has all sorts of strikes against it. For one, it's an Israeli biotech company. I like Israel just fine, but there's definitely something wrong with the way they regulate biotech companies over there. Some of the Israeli companies I despise are Alcobra and Pluristem. I'm also a bagholder on others which I tried playing for a scam bounce, like BioLineRx and Brainstorm. These companies just don't seem designed to develop real drugs. As I delineated in detail on CAPS last September, the results of the phase II trial of VB-111 for GBM made absolutely no sense when compared to the trial protocol on The company ignored the email I sent them requesting clarification. I successfully shorted the stock but left the lion's share of gains on the table.

The current story for Vascular Biogenics is the phase III GLOBE trial of VB-111 + Avastin vs Avastin alone for recurrent GBM, which is proceeding under an SPA. Interim data is expected in H1 2017. Recurrent GBM has been a short-term gold mine and a long term graveyard for companies like Northwest, Immunocellular, Agenus, and Peregrine. The company will also present preliminary OS data from an ongoing phase II trial of VB-111 for recurrent platinum-resistant Mullerian cancer at ASCO next week. They had 33M in cash at the end of March and burn 3-5M per quarter, not much for a partnerless company with a legitimate phase III trial in progress. I'm hoping that management will remain true to form and spin dubious ASCO data into a price spike that will fuel another dilutive financing for them and another profitable short for me.


Member Avatar Hendrickson71 (< 20) Submitted: 9/22/2015 4:35:53 PM : Outperform Start Price: $9.77 NASDAQ:VBLT Score: -204.38

I think better price can be had (unless of course more news). Volume won't match todays for a bit. Short term pull back is what I see.


Find the members with the highest scoring picks in VBLT.

Score Leader


zzlangerhans (97.41) Score: +188.62

The Score Leader is the player with the highest score across all their picks in VBLT.

Member Name Member
Call Time
Score Commentary
zzlangerhans 97.41 5/31/2016 Underperform 1Y $3.64 -38.74% +109.53% +148.27 4 Comments
JoeySolitro1 99.99 3/12/2018 Underperform 5Y $2.48 -9.90% +58.25% +68.15 0 Comment
NextGenStock 65.17 9/14/2020 Outperform 5Y $1.22 +82.68% +30.67% +52.01 0 Comment
BogotaClub 30.01 6/4/2020 Outperform 5Y $1.29 +72.87% +41.80% +31.07 0 Comment
DrDoofenshmirtz 44.52 2/7/2019 Underperform 5Y $1.45 +53.79% +62.86% +9.07 0 Comment
RayNobleEsq 99.93 4/2/2020 Underperform 5Y $1.26 +76.98% +79.36% +2.38 0 Comment
RyanCoke 91.50 2/11/2019 Underperform NS $1.34 +66.42% +62.92% -3.49 0 Comment
ClientNein 99.45 2/6/2019 Underperform 5Y $1.33 +67.67% +61.67% -6.00 0 Comment
liszewski 99.80 11/12/2018 Underperform 5Y $1.31 +70.23% +59.10% -11.13 0 Comment
midastouch017 < 20 6/9/2021 Outperform 3Y $2.58 -13.61% +4.34% -17.95 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VBLT.